This guide explores key considerations for a successful transition to Phase II, covering dosage form evolution, sub-optimal clinical data responses and CDMO partnership.
Evolving the Dosage Form
Moving from simple Phase I formulations to Phase II presentations requires planning for stability, manufacturability and patient acceptability.
Responding to Sub-Optimal Data
Unexpected exposure results can often be addressed through formulation changes if the strategy allows flexibility.
The Role of the CDMO
A partner with development and manufacturing capability streamlines the transition and protects timelines.
About This White Paper
This white paper is published by Upperton and curated by Biotechnology Media Insights, a trusted source for pharmaceutical and biotechnology research, technical guides and industry analysis.